Abstract
Background: Moderate kidney dysfunction is independently associated with increased cardiovascular mortality. Sudden cardiac arrest (SCA) accounts for at least 25% of chronic kidney disease (CKD) mortality. Methods We conducted a case-control study within an ongoing, prospective, community-based investigation of out-of-hospital SCA in the Portland, Oregon, metropolitan area (population ~ 1 million) from February 1st, 2002, to December 31st, 2020. Analysis included individuals aged 40 to 75 who experienced SCA (cases) and individuals with no history of SCA (controls), with creatinine levels measured prior to SCA/enrollment. Moderate CKD was defined by an estimated glomerular filtration rate (eGFR) of 30 to <60 mL/min/1.73 m2 (2021 CKD-EPI formula). A population-based SCA study in Southern California was used for validation. Results We compared 2,068 SCA cases and 852 controls (mean ages: 61.4±8.5 and 62.7±8.0 years; males: 69.9% and 67.4%). SCA cases had more moderate CKD (17.7% vs. 14.7%, p<0.001) and lower eGFR (74.7 vs. 80.9 mL/min/1.73 m2, p<0.001) than controls. Multivariable regression demonstrated that moderate CKD was an independent risk factor for SCA (OR: 1.33, 95% CI: 1.03-1.72). Each 10 mL/min/1.73 m2 eGFR drop below 90 increased SCA risk (OR: 1.24, 95% CI: 1.18-1.31). Similar findings were observed in the validation cohort (817 SCA and 3,249 controls), where moderate CKD was associated with SCA (OR: 1.51, 95% CI: 1.16-1.97). Conclusion Moderate CKD is associated with an increased risk of SCA in the general population. Further research into the potential integration of moderate renal dysfunction into SCA risk stratification are warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Chugh has received funding from National Institutes of Health, National Heart Lung and Blood Institute Grants R01HL145675 and R01HL147358 for this work. Dr. Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai, Los Angeles.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review boards of Cedars-Sinai Medical Center, Oregon Health & Science University, and all relevant hospitals/health systems have approved the study protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.